Zhao, Sizheng StevenYoshida, KazukiJones, Gareth T.Hughes, David M.Duffield, Stephen J.Tedeschi, Sara K.Lyu, HouchenMoots, Robert J.Solomon, Daniel H.Goodson, Nicola J.2019-08-282019-08-282019-07-22Zhao, S S, Yoshida, K, Jones, G T, Hughes, D M, Duffield, S J, Tedeschi, S K, Lyu, H, Moots, R J, Solomon, D H & Goodson, N J 2019, 'Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis', Arthritis Research & Therapy, vol. 21, no. 1, 177. https://doi.org/10.1186/s13075-019-1958-z1478-6354PubMedCentral: PMC6647300Mendeley: 2c082130-ea08-36a1-a666-a867c4731854ORCID: /0000-0003-0016-7591/work/83703976http://hdl.handle.net/2164/12801Availability of data and materials BSRBR-AS data are held at the University of Aberdeen. Funding The BSRBR-AS is funded by the British Society for Rheumatology (BSR) who have received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments. They have no input in determining the topics for analysis or work involved in undertaking it. SZ was supported by awards from the Royal College of Physicians (John Glyn bursary) and Royal Society of Medicine (Kovacs fellowship). KY received financial support for his doctoral study from the Pharmacoepidemiology Program at the Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer and ASISA) and Honjo International Scholarship Foundation. DHS was supported by grants from the National Institute of Health (NIH-P30-AR072577 (VERITY) and NIH-K24AR055989) and has received funding from Abbvie and Amgen unrelated to this work. Acknowledgements We are grateful to Professor Gary Macfarlane (Chief Investigator of BSRBR-AS) and the staff of the BSRBR-AS register who are currently Claudia Zabke, Elizabeth Ferguson-Jones, Maureen Heddle, Nafeesa Nazlee and Barry Morris, and to the recruiting staff at the clinical centres, details of which are available at: https://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritis7585366engAxial spondyloarthritisTNF inhibitorBiologic DMARDsPersistenceEffectivenessResponseDiscontinuationMarginal structural modelR Medicine (General)Supplementary DataR1Journal article10.1186/s13075-019-1958-zhttp://www.mendeley.com/research/smoking-status-causespecific-discontinuation-tumour-necrosis-factor-inhibitors-axial-spondyloarthrit211